Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 184

Results For "Pharma"

3786 News Found

Merck inks MoU with KAIST to advance scientific collaboration
News | May 30, 2024

Merck inks MoU with KAIST to advance scientific collaboration

Partnership to facilitate collaborative research in academia and industry to further progress in life sciences


Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
News | May 29, 2024

Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history


Strides receives USFDA approval for Sucralfate oral suspension, 1gm/10 mL
Drug Approval | May 29, 2024

Strides receives USFDA approval for Sucralfate oral suspension, 1gm/10 mL

Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation


Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth
News | May 29, 2024

Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth

Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas


Bluecrux supports Sanofi in harnessing AI to transform supply chains
Supply Chain | May 28, 2024

Bluecrux supports Sanofi in harnessing AI to transform supply chains

Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.


Ascentage releases results from multiple clinical studies of its lead drug candidates
Diagnostic Center | May 28, 2024

Ascentage releases results from multiple clinical studies of its lead drug candidates

These abstracts report on the company's three lead drug candidates, including olverembatinib


AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
News | May 28, 2024

AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr

Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth


Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction
Diagnostic Center | May 27, 2024

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression


Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast
Diagnostic Center | May 25, 2024

Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast

ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset